Brian Roberts, the CFO of Insulet Corporation (PODD), Interviews with The Wall Street Transcript

March 17, 2014

67 WALL STREET, New York - March 17, 2014 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Affordable Care Act - Aging U.S. Population - End Market Improvement - Biotech, Pharma and Medical Device Convergence - Changing Competitive Dynamics

Companies include: Insulet Corporation (PODD) and many more.

In the following excerpt from the Medical Devices Report, the CFO of Insulet Corporation (PODD) discusses company strategy and the outlook for this vital industry:

TWST: So are all of your revenues from OmniPod sales, and if they are, can you speak to the breakdown of revenues geographically, say in the last year or so?

Mr. Roberts: Not all of them. Probably around 15% of our overall revenue comes from an acquisition that we did with a company back in 2011 called Neighborhood Diabetes. Neighborhood is a full-service diabetes supplier and distributor. If you need other diabetes-related supplies beyond just the OmniPod, you can get it through our Neighborhood subsidiary.

A main reason we brought them into the fold was that diabetes - within the world of medical devices, in a lot of cases - is a very direct-to-consumer type of a business. For the majority of the customers, we ship OmniPod reorders as a package every 90 days. So that kind of company-to-your-doorstep type of an approach is very different than if you think about a lot of the other different kinds of med-tech areas, be it cardiac or other different conditions.

So beyond that, the Neighborhood group makes up a piece of revenues, and we do receive international revenue. We partner with a company called Ypsomed, which is a Switzerland-based company, as our European distributor of the product, and GlaxoSmithKline distributes the product in Canada. We haven't disclosed what that percentage of revenue is in total for international, but suffice it to say, it's probably in the mid-single percentages, in that range.

TWST: How large is the overall market, and how do you expect it to change?

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.